Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of "Buy" by Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $26.60.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Citizens Jmp raised Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. Wedbush reaffirmed an "outperform" rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Finally, JMP Securities assumed coverage on Astria Therapeutics in a research report on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price on the stock.

Astria Therapeutics Trading Up 12.4 %

Shares of Astria Therapeutics stock opened at $4.62 on Wednesday. The stock's fifty day simple moving average is $5.67 and its 200 day simple moving average is $8.22. The company has a market capitalization of $260.73 million, a PE ratio of -2.21 and a beta of 0.68. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. Analysts predict that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Hedge funds have recently modified their holdings of the stock. Barclays PLC boosted its position in Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock valued at $1,020,000 after purchasing an additional 38,321 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Astria Therapeutics by 101.7% in the third quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company's stock valued at $431,000 after buying an additional 19,735 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Astria Therapeutics by 51.3% in the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company's stock valued at $190,000 after buying an additional 7,218 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Astria Therapeutics during the fourth quarter worth $107,000. Finally, Rhumbline Advisers raised its position in Astria Therapeutics by 2.3% during the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock worth $556,000 after acquiring an additional 1,381 shares in the last quarter. Institutional investors own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.